Astonea Labs share price
BSE: 544409Pharmaceuticals & BiotechnologySmall Cap
ASTONEA LABS LIMITED · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 2025
Last close ₹323.00down ₹1.00 (0.31%)
Share price at the BSE close on 19 Oct 2026. Previous close ₹324.00.
19 Oct: open ₹323.00, high ₹323.00, low ₹323.00
52-week range of traded prices to 19 Oct 2026
₹118.00Low, 24 Nov 2025₹369.00High, 18 Sep 2026
- Under BSE's long-term additional surveillance, stage I, on the list for 27 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹340 Cr2,441st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 75.19
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.94
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it, the company's own balance sheet from before it began consolidating; the two agree where both are first on record.
- 12.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.75
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 1,000
Results
Standalone, as consolidated accounts are on record for only 1 of the last ten years; ₹ crore.Astonea Labs half-yearly results
Half year to Mar 2026, against the half year before
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹81 Crup 22.63%
- Net profitNet profit. The pill is the change in net profit against the half year before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹3.10 Crup 118.53%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 3.8%
Revenue by half year
Peak revenue ₹81 Cr, half year to Mar 2026; lowest ₹47 Cr, half year to Sep 2024
Net profit by half year, a loss in red
| ₹ crore | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 47.3 | 50.2 | 66.3 | 81.3 |
| Net profit | 2.1 | 3.2 | 1.4 | 3.1 |
| Net margin | 4.5% | 6.4% | 2.1% | 3.8% |
Standalone. The 4 half years from Sep 2024, the first on record. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹148 Crup 51.34%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹4.52 Crdown 15.61%
- Net margin
- 3.1%
Revenue by year
Peak revenue ₹148 Cr, year to Mar 2026; lowest ₹98 Cr, year to Mar 2025
Net profit by year, a loss in red
| ₹ crore | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 98 | 148 |
| Net profit | 5 | 5 |
| Net margin | 5.5% | 3.1% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, DRUGS, PHARMACEUTICALS AND COSMETICS, which carries all its revenue.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Astonea Labs insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Promoters and promoter group9 purchases, 0 sales₹0.43 CrNo saleNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.₹0.43 Cr
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Astonea Labs competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Astonea Labs in market cap. Astonea Labs' own figures are from its last trade, on 19 Oct 2026.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Infinium PharmachemINFINIUM | 429 | 35.28 | 3.54 | +21.8% | +41.8% | 10.5% | – | 0.00% |
 Jenburkt PharmaceuticalsJENBURPH | 387 | 11.78 | 1.96 | +9.1% | +1.2% | 17.8% | 19.2% | 2.36% |
 Medicamen BiotechMEDICAMEQ | 358 | – | 1.30 | +24.7% | – | – | 3.7% | 0.39% |
 Aarey Drugs & PharmaceuticalsAAREYDRUGS | 344 | – | – | −7.7% | – | – | 1.8% | 0.00% |
 Astal LaboratoriesASTALLTD | 289 | 29.67 | 0.87 | +122.7% | +4.4% | 5.4% | 4.2% | 0.00% |
 Lyka LabsLYKALABS | 280 | – | 3.03 | −2.6% | – | −9.2% | −8.0% | 0.00% |
 Ambalal Sarabhai EnterprisesAMBALALSA | 272 | 20.09 | 1.72 | +4.9% | +5.8% | 9.1% | 5.0% | 0.00% |
 Everest OrganicsEVERESTO | 257 | 48.97 | 3.41 | +5.5% | −15.2% | 7.2% | 10.5% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Astonea Labs announcements
Oct 2026
9 Oct · Intimation Regarding Change In The Corporate Identification Number (CIN) Of The Company Consequent Upon Alteration Of The Object Clause Of The Memorandum Of Association
8 Oct · Incorporation Of Proposed Subsidiary- Longevity Science Private Limited
Sep 2026
Astonea Labs share price by year
Each calendar year to 2025.Astonea Labs share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 163.50 | – | 182.30 | 135.00 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2025 is from its first session, 3 Jun 2025.
Recent sessions
The 9 trading days to 12 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 12 Oct 2026 | 323.95 | 324.00 | 323.95 | 324.00 | 323.98 | 2,000 |
| 9 Oct 2026 | 316.35 | 324.00 | 316.35 | 324.00 | 319.16 | 4,000 |
| 6 Oct 2026 | 334.00 | 334.00 | 334.00 | 334.00 | 334.00 | 1,000 |
| 5 Oct 2026 | 335.00 | 335.00 | 335.00 | 335.00 | 335.00 | 1,000 |
| 1 Oct 2026 | 345.00 | 345.00 | 345.00 | 345.00 | 345.00 | 1,000 |
| 30 Sep 2026 | 348.15 | 348.15 | 348.15 | 348.15 | 348.15 | 1,000 |
| 25 Sep 2026 | 338.00 | 338.00 | 338.00 | 338.00 | 338.00 | 1,000 |
| 24 Sep 2026 | 333.00 | 333.00 | 333.00 | 333.00 | 333.00 | 1,000 |
| 23 Sep 2026 | 332.45 | 332.45 | 332.45 | 332.45 | 332.45 | 1,000 |
Prices in ₹ per share as traded, not adjusted.
Company details
- BSE code
- 544409
- ISIN
- INE0TG901011
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.astonea.org
- CIN
- L24304CH2017PLC041482
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 2017
- Registered office
- SCO 186-187, 2nd Floor, Cabin No. 206, SECTOR 8 C, Sector 8, Chandigarh 160009, Haryana
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments